FDA Approved: CABLIVI — Original Application (Genzyme Corporation)

View source ↗

Summary

FDA approved CABLIVI (caplacizumab) from Genzyme for the treatment of adults with acquired thrombotic thrombocytopenic purpura.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Thrombotic Thrombocytopenic Purpura

Drugs mentioned

• CABLIVI (CAPLACIZUMAB)

Snippet

ORIG AP for CABLIVI (CAPLACIZUMAB)